​​Sterile and antiviral packaging: How will advanced technologies unwrap growth potential

[Image courtesy of Wikipedia]

Over the years, consumer behavior has changed massively. The impact of COVID-19 has stoked consumers’ hygiene concerns. Furthermore, the ability of the SARS-CoV-2 virus to sit for longer durations on the surface has been fuelling demand for sterile and antiviral packaging, considering the antibacterial properties they exhibit.

Global demand for sterile, antiviral and contaminant-free packaging solutions is growing at a swift rate. With stakeholders becoming highly health-conscious, various industries — ranging from food and beverages to pharmaceuticals — are investing in advanced packaging solutions. According to the ESOMAR-certified, market research and intelligence firm Future Market Insights, the global market for sterile and antiviral packaging is poised to register a CAGR of 5.3% from 2022 to 2032, valued at $25 billion by the end of 2022.

Factors like clean and…

Read more
  • 0

Vivera picks up new patent for electronic dose-controlled drug delivery devices

[Image from Vivera]

Vivera announced today that it received a third U.S. patent for its Zicoh electronic dose-controlled drug delivery device portfolio.

Newport Beach, California-based Vivera’s latest patent from the U.S. Patent and Trademark Office (USPTO) secures Zicoh’s rights as a smart dosing system with automated delivery, measurement, and management for oral format medications, including pills, capsules and tablets.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Lilly says proposed $2.1B facility investment could create up to 500 jobs 

Eli Lilly and Company (NYSE: LLY) has announced plans to build two new factories in Indiana. The plants will bolster its supply of active ingredients and new therapeutic modalities.

The plants will be based in LEAP Lebanon Innovation and Research District in Boone County, Indiana.

The proposal could ultimately create as many as 500 new jobs.

The company notes in a press release that the investment is “contingent upon local zoning and annexation approvals.”

Lilly CEO David A. Ricks, who has called for the state to become more competitive, stressed that the company is “committed to investing and innovating in Indiana.”

Eli Lilly was founded in 1876 in Indianapolis, where the company remains headquartered.

“These new sites will add capacity in support of our growing pipeline of innovative medicines, while also creating more high-tech jobs for Hoosiers,” Ricks said in a news release. “We are plea…

Read more
  • 0

Entegris opens Life Sciences Technology Center in Massachusetts

Entegris (Nasdaq:ENTG) announced today that it opened a new Life Sciences Technology Center in Billerica, Massachusetts.

The new Life Sciences Technology Center was built to offer life sciences customers the opportunity to leverage Entegris’ cold-chain supply expertise to optimize processes, reduce costs and increase speed to market.

Entegris’ tools and technologies will be brought together at the laboratory space, according to a news release, and customers can test equipment for freeze and thaw processes to determine which products best fit their needs.

The company said that, as part of its manufacturing challenges solutions, it is now offering Aramus-shaped 2D single-use bags with custom shapes, sizes and assembly configurations for customers’ space and function requirements. They have been designed to be resistant to extreme cold temperatures and to withstand gamma sterilization, making them an option for fr…

Read more
  • 0

MedTrace Pharma moves forward on 15 O-water imaging tech

MedTrace Pharma seeks to bring 15 O-water production inside hospitals with its P3 automated point-of-care chemistry system. [Image courtesy of  MedTrace Pharma]

MedTrace Pharma announced the first person scanned in its Rapid-Water-Flow Phase 3 clinical trial, further testing its tech to bring 15 O-water to imaging.

The first subject scan took place at Aarhus University Hospital in Denmark, using 15 O-water produced, dosed and injected through MedTrace’s P3 automated delivery system. The clinical trial aims to evaluate the use of 15 O-water in PET scans to diagnose coronary artery disease. The trial kickoff, announced on May 20, comes about two months after MedTrace received FDA approval of the company’s Investigational New Drug (IND) application and the approval to commence the trial.

Oxygen-15 labeled water has a reputation as a gold-standard radioactive tracer for PET imaging, but supply chain …

Read more
  • 0

Pfizer, BioNTech moving forward on seeking COVID-19 vaccine EUA for youngest children

Pfizer-BioNTech COVID-19 vaccine. [Image courtesy of Wikimedia Commons]

Pfizer (NYSE:PFE) and BioNTech (Nasdaq:BNTX) announced today that data supports a third dose of their COVID-19 vaccine in young children.

Topline safety, immunogenicity and vaccine efficacy data from a Phase 2/3 trial evaluating a third 3-µg dose of the vaccine — marketed in the U.S. as Comirnaty — showed a strong immune response and a favorable safety profile similar to placebo in children aged six months to under five years old.

In the trial, 1,678 children received a third dose of the vaccine at least two months after second dose, while omicron was the predominant variant. Non-inferiority was met for both the 6-24 month-old population and the 2-under 5-year-old population for both primary endpoints, with the vaccine well tolerated, leading to no new safety signals.

Vaccine efficacy (a secondary endpoint) registered at 80.…

Read more
  • 0

How pharma can optimize for right-the-first-time drug manufacturing and sustainability

[Image by Gerd Altmann from Pixabay

The pharmaceutical industry is gradually going green. More pharma companies are embracing sustainability metrics and striving to reduce corporate emissions and their footprint.

More than 25% of major pharma and biopharma companies are committed to reaching net-zero carbon emissions by 2050. Many are also committed to ensuring equal access to medicine for the 2 billion people worldwide that are currently underserved and rely on the United Nations Sustainable Development Goals (UN SDGs). Those initiatives are designed to improve human and planet health while helping achieve sustainable business practices.

Working toward a prosperous and equitable future while building healthy communities can directly support current and future business operations for pharma and biopharma organizations. These companies have concluded there does not need to be a choice between being envi…

Read more
  • 0

Festo introduces smart pipette for automated dispensing systems

The German industrial control and automation firm Festo has introduced its DHOP closed-loop smart-pipette for automated, high-speed dispensing systems used for pharmaceutical, biotech and cosmetic R&D.

The Esslingen, Germany-based company announced the pipette at the Interphex tradeshow scheduled for May 24-26 in New York City.

The DHOP pipette will formally be available in mid-2022.

Festo notes that its low-force-tips for the DHOP are well suited for automated pipette applications demanding precision, validation and process monitoring.

Integrated pressure sensors validate the performance of every dispense operation.

Festo also notes that sensor data can track dispense volumes and fluid characteristics.

Festo closed-loop pipettes can aspirate and dispense a variety of volumes while keeping tabs on key performance indicators related to pressure, flow and liquid level.

In addition, the smart pipettes can send alerts when tip…

Read more
  • 0

GlaxoSmithKline officially rebrands as GSK

GlaxoSmithKline (NYSE:GSK) has long gone by its acronym GSK. Now, the abbreviation is the company’s official name.

GlaxoSmithKline had announced its plan to change the name in an earnings announcement in April 27.

The London Stock Exchange and the New York Stock Exchange will update the company’s name in “due course,” as the company explained in a news release.

GlaxoSmithKline got its name from the 2000 merger of Glaxo Wellcome and SmithKline Beecham. In that deal, Glaxo Wellcome paid $75.7 billion to acquire its then competitor, creating what WSJ called in 2000 the “world’s No. 1 drugmaker.”

Now, GSK is in the process of creating a consumer health spinoff known as ‘Haleon.’

GSK’s consumer segment makes an array of products, including Centrum vitamins, Sensodyne toothpaste, and the pain-reliever brands Excedrin, Advil and Panadol.

The company’s decision to simplify its…

Read more
  • 0

FDA denies EUA for COVID-19 indication of SSRI fluvoxamine

[Fluvoxamine image from Wikipedia]

The infectious disease physician-scientist Dr. David R Boulware filed for emergency use authorization (EUA) of fluvoxamine, an established selective serotonin reuptake inhibitor (SSRI) whose brand name is Luvox.

The FDA has rejected the application, explaining the treatment benefit of the drug was “not persuasive” in the TOGETHER study that was the basis of the EUA application. 

The randomized, double-blind study had a composite endpoint consisting of a reduction of emergency room visits due to worsening COVID-19 infection and hospitalization resulting from COVID-19 up to 28 days after randomization. 

The study concluded that fluvoxamine reduced COVID-19 hospitalizations by as much as 30%.

Although the study met its primary endpoint, FDA noted that “the results were primarily driven by a reduction in the emergency department visits lasting greater than 6…

Read more
  • 0

Seagen CEO Siegall resigns after domestic abuse arrest

(Nasdaq:SGEN) has announced that its CEO Clay Siegall has resigned following a domestic abuse arrest in April.

Police charged Siegall with fourth-degree misdemeanor assault. He maintains his innocence.

The company has named its lead independent director Felix Baker to assume the role of chair of the board of directors. Seagen Chief Medical Officer Dr. Roger Dansey will serve as interim CEO.

Baker said in a statement that the company’s board has “great confidence in the leadership of Roger Dansey, the senior management team and the nearly 3,000 employees to continue Seagen’s impressive growth trajectory.”

SGEN shares rose about 5% to $142.54.

Siegall was among the highest-paid executives in the pharmaceutical salary, raking in $18.9 million in total compensation last year.

Earlier this month, he took a leave of absence from the company.

Seagen announced an investigation of domestic abuse allegations against Siegall, which will…

Read more
  • 0

Aptar CSP Technologies launches Activ-Blister for oral slide dose drugs in EMEA

[Image courtesy of Aptar CSP Technologies]

Material science specialist Aptar CSP Technologies (Auburn, Alabama) has opened a new manufacturing site in Europe that can produce its Activ-Blister technologies for oral slide dose drugs.

Three companies were involved in opening the facility, including Aptar CSP, pharma packaging equipment firm Uhlmann and Ivers-Lee, a contract manufacturer.

Uhlmann provided a blister machine validated to package oral solid dose drug products with Aptar CSP’s Activ-Blister packaging. The machine can produce up to 250 blisters per minute.

Aptar CSP notes that a contract manufacturing organization in EMEA will provide customer support for local companies.

The company plans to eventually introduce the technology to the Asian market.

“Expanding global manufacturing sites for Activ-Blister technology reflects our commitment to delivering global access to inno…

Read more
  • 0